Research from our group and others has demonstrated that epithelial-mesenchymal transition (EMT) is a central phenomenon occurring in KRAS-mutant lung cancer, which contributes to intracellular tumor heterogeneity, increased metastatic potential, therapeutic resistance to pharmacological agents, and poor patient outcomes (9–11). This evidence concerns the gene KRAS and lung carcinoma.